JP2013508281A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013508281A5 JP2013508281A5 JP2012534309A JP2012534309A JP2013508281A5 JP 2013508281 A5 JP2013508281 A5 JP 2013508281A5 JP 2012534309 A JP2012534309 A JP 2012534309A JP 2012534309 A JP2012534309 A JP 2012534309A JP 2013508281 A5 JP2013508281 A5 JP 2013508281A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- pyridin
- hydroxy
- oxo
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 C*1c2cccnc2C(*C(*)=O)C(*)(*)C(*)(*)C1(C)* Chemical compound C*1c2cccnc2C(*C(*)=O)C(*)(*)C(*)(*)C1(C)* 0.000 description 3
- DKOVETTYBHNFNO-UHFFFAOYSA-O CC(C)N(CCc(c(N1)ccc2)[n+]2O)C1=O Chemical compound CC(C)N(CCc(c(N1)ccc2)[n+]2O)C1=O DKOVETTYBHNFNO-UHFFFAOYSA-O 0.000 description 1
- BKEFAAUTUUQOMM-UHFFFAOYSA-N CC(C)N(CCc1ncccc1N1)C1=O Chemical compound CC(C)N(CCc1ncccc1N1)C1=O BKEFAAUTUUQOMM-UHFFFAOYSA-N 0.000 description 1
- BVLLDWVRHRWMOK-UHFFFAOYSA-N CC1(C)C=C(CN(C)C(N2)=O)C2=NC=C1 Chemical compound CC1(C)C=C(CN(C)C(N2)=O)C2=NC=C1 BVLLDWVRHRWMOK-UHFFFAOYSA-N 0.000 description 1
- FDQDEYVZTNVCIF-UHFFFAOYSA-O CCN(CCc(c(N1)ccc2)[n+]2O)C1=O Chemical compound CCN(CCc(c(N1)ccc2)[n+]2O)C1=O FDQDEYVZTNVCIF-UHFFFAOYSA-O 0.000 description 1
- CHZRTXKKKOYGJO-UHFFFAOYSA-N CN(CCc1ccccc1N1)C1=O Chemical compound CN(CCc1ccccc1N1)C1=O CHZRTXKKKOYGJO-UHFFFAOYSA-N 0.000 description 1
- VBYNMZORUPNRKR-UHFFFAOYSA-N CN(Cc1c(N2)nccc1)C2=O Chemical compound CN(Cc1c(N2)nccc1)C2=O VBYNMZORUPNRKR-UHFFFAOYSA-N 0.000 description 1
- FBKOMTLPDDPCSE-UHFFFAOYSA-O CN(Cc1c[n+](=C)ccc1N1)C1=O Chemical compound CN(Cc1c[n+](=C)ccc1N1)C1=O FBKOMTLPDDPCSE-UHFFFAOYSA-O 0.000 description 1
- PYEHNKXDXBNHQQ-UHFFFAOYSA-N CN(c1ccccc1N1)C1=O Chemical compound CN(c1ccccc1N1)C1=O PYEHNKXDXBNHQQ-UHFFFAOYSA-N 0.000 description 1
- JWBRNYGXJYMMSI-UHFFFAOYSA-N CN(c1cccnc1N1)C1=O Chemical compound CN(c1cccnc1N1)C1=O JWBRNYGXJYMMSI-UHFFFAOYSA-N 0.000 description 1
- HHQIYFYEJOWYJM-POEMVANMSA-N C[NH+2]/C=C(/CN(C)C(N1)=O)\C1=C/C=C Chemical compound C[NH+2]/C=C(/CN(C)C(N1)=O)\C1=C/C=C HHQIYFYEJOWYJM-POEMVANMSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25147709P | 2009-10-14 | 2009-10-14 | |
| US61/251,477 | 2009-10-14 | ||
| PCT/US2010/052433 WO2011046997A1 (en) | 2009-10-14 | 2010-10-13 | Cgrp receptor antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015092727A Division JP6109874B2 (ja) | 2009-10-14 | 2015-04-30 | Ｃｇｒｐ受容体アンタゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013508281A JP2013508281A (ja) | 2013-03-07 |
| JP2013508281A5 true JP2013508281A5 (enExample) | 2013-11-28 |
| JP5836279B2 JP5836279B2 (ja) | 2015-12-24 |
Family
ID=43242489
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012534309A Active JP5836279B2 (ja) | 2009-10-14 | 2010-10-13 | Ｃｇｒｐ受容体アンタゴニスト |
| JP2015092727A Active JP6109874B2 (ja) | 2009-10-14 | 2015-04-30 | Ｃｇｒｐ受容体アンタゴニスト |
| JP2017043761A Active JP6258537B2 (ja) | 2009-10-14 | 2017-03-08 | Ｃｇｒｐ受容体アンタゴニスト |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015092727A Active JP6109874B2 (ja) | 2009-10-14 | 2015-04-30 | Ｃｇｒｐ受容体アンタゴニスト |
| JP2017043761A Active JP6258537B2 (ja) | 2009-10-14 | 2017-03-08 | Ｃｇｒｐ受容体アンタゴニスト |
Country Status (35)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8314117B2 (en) * | 2009-10-14 | 2012-11-20 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| US8669368B2 (en) * | 2010-10-12 | 2014-03-11 | Bristol-Myers Squibb Company | Process for the preparation of cycloheptapyridine CGRP receptor antagonists |
| US8748429B2 (en) * | 2011-04-12 | 2014-06-10 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| HRP20171620T1 (hr) * | 2012-02-27 | 2017-12-01 | Bristol-Myers Squibb Company | N- (5s, 6s, 9r) - 5 amino- 6 - (2, 3 - difluorofenil) -6, 7, 8, 9 - tetrahidro - 5h - ciklohepta [b]piridin-9 -il- 4 - (2 - okso-2, 3 - dihidro - 1h - imidazo [4, 5 -b]piridin - 1 - il) piperidin - 1 - karboksilat, hemisulfatna sol |
| US9227973B2 (en) * | 2012-05-09 | 2016-01-05 | Merck Sharp & Dohme Corp. | Pyridine CGRP receptor antagonists |
| EP2815749A1 (en) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
| TW201718574A (zh) * | 2015-08-12 | 2017-06-01 | 美國禮來大藥廠 | Ｃｇｒｐ受體拮抗劑 |
| GB201519196D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| GB201519194D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP receptor antagonists |
| GB201519195D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| GB201707938D0 (en) | 2017-05-17 | 2017-06-28 | Univ Sheffield | Compounds |
| JP2021519288A (ja) | 2018-03-25 | 2021-08-10 | バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドＢｉｏｈａｖｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｈｏｌｄｉｎｇ Ｃｏｍｐａｎｙ Ｌｔｄ． | Ｃｇｒｐ関連障害のためのリメゲパント |
| CN114805206B (zh) * | 2021-01-27 | 2025-01-14 | 奥锐特药业(天津)有限公司 | 高光学纯度瑞美吉泮中间体的工业化制备方法 |
| CA3212151A1 (en) | 2021-03-02 | 2022-09-09 | Cgrp Diagnostics Gmbh | Treatment and/or reduction of occurrence of migraine |
| WO2023026205A1 (en) | 2021-08-24 | 2023-03-02 | Cgrp Diagnostics Gmbh | Preventative treatment of migraine |
| CN115850266A (zh) * | 2021-09-26 | 2023-03-28 | 奥锐特药业(天津)有限公司 | 瑞美吉泮新晶型及其制备方法 |
| CN116554164B (zh) * | 2022-01-27 | 2025-10-03 | 奥锐特药业(天津)有限公司 | 一种瑞美吉泮的制备方法 |
| WO2023175632A1 (en) * | 2022-03-17 | 2023-09-21 | Msn Laboratories Private Limited, R&D Center | Solid state forms of (5s,6s,9r)-5-amino-6-(2,3difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)-1-piperidinecarboxylate hemisulfate and processes for preparation thereof |
| CN116478211B (zh) * | 2022-04-19 | 2023-10-24 | 石家庄迪斯凯威医药科技有限公司 | 一种新型cgrp受体拮抗剂及其用途 |
| CN115060824B (zh) * | 2022-06-14 | 2024-03-12 | 浙江宏元药业股份有限公司 | 一种瑞米吉泮中间体对映异构体杂质的液相色谱检测方法 |
| WO2024022434A1 (zh) * | 2022-07-29 | 2024-02-01 | 熙源安健医药（上海）有限公司 | 吡啶并环庚烷类衍生物及其制备方法和用途 |
| CN115677694A (zh) * | 2022-11-30 | 2023-02-03 | 南通常佑药业科技有限公司 | 一种瑞美吉泮的合成方法 |
| WO2024180562A1 (en) * | 2023-03-02 | 2024-09-06 | Natco Pharma Limited | A process for the preparation of pure crystalline rimegepant and its salts thereof |
| CN116768938B (zh) * | 2023-05-17 | 2025-11-11 | 南京艾德凯腾生物医药有限责任公司 | 一种铁催化剂及瑞美吉泮中间体的制备方法 |
| WO2025061177A1 (zh) * | 2023-09-21 | 2025-03-27 | 成都康弘药业集团股份有限公司 | 一种治疗cgrp相关障碍的小分子药物 |
| CN117486798B (zh) * | 2023-12-21 | 2025-02-07 | 南京威凯尔生物医药科技有限公司 | 一种瑞美吉泮中间体盐酸盐的晶型及其制备方法 |
| WO2025193980A2 (en) * | 2024-03-13 | 2025-09-18 | CNS Biosciences, Inc. | Method of treating neuropathic pain using an anti-cgrp inhibitor |
| CN119707808B (zh) * | 2024-12-23 | 2025-12-05 | 上海彩迩文生化科技有限公司 | 一种制备cgrp受体拮抗剂中间体的方法 |
| CN121949205A (zh) * | 2025-04-15 | 2026-05-01 | 常州制药厂有限公司 | 一种瑞美吉泮中间体及其制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2355B1 (en) * | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
| AU2005219785B2 (en) | 2004-03-05 | 2010-05-27 | Msd K.K. | Cycloalkanopyridine derivative |
| BRPI0517418A (pt) | 2004-10-13 | 2008-10-07 | Merck & Co Inc | composto, composição farmacêutica, e, métodos para antagonismo de atividade do receptor de cgrp em um mamìfero, para tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca ou cefalgia, e de tratamento ou prevenção de dores de cabeça de enxaqueca, cefalgias, e dores de cabeça |
| US20060084708A1 (en) | 2004-10-14 | 2006-04-20 | Bayer Materialscience Llc | Rigid foams with good insulation properties and a process for the production of such foams |
| US7745427B2 (en) | 2004-10-22 | 2010-06-29 | Merck Sharp & Dohme Corp. | CGRP receptor antagonists |
| AU2007238894A1 (en) | 2006-04-10 | 2007-10-25 | Merck Sharp & Dohme Corp. | Process for the preparation of pyridine heterocycle CGRP antagonist intermediate |
| US8143403B2 (en) | 2008-04-11 | 2012-03-27 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| US8044043B2 (en) | 2008-04-11 | 2011-10-25 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| US8314117B2 (en) * | 2009-10-14 | 2012-11-20 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
-
2010
- 2010-10-12 US US12/902,714 patent/US8314117B2/en active Active
- 2010-10-13 MX MX2012004182A patent/MX2012004182A/es active IP Right Grant
- 2010-10-13 AU AU2010306954A patent/AU2010306954B2/en active Active
- 2010-10-13 NZ NZ599281A patent/NZ599281A/xx unknown
- 2010-10-13 KR KR1020177018206A patent/KR101875353B1/ko active Active
- 2010-10-13 CN CN201080056672.4A patent/CN102656159B/zh active Active
- 2010-10-13 BR BR112012008828-9A patent/BR112012008828B1/pt active IP Right Grant
- 2010-10-13 EP EP10768347.6A patent/EP2488512B1/en active Active
- 2010-10-13 DK DK10768347.6T patent/DK2488512T3/en active
- 2010-10-13 PL PL10768347T patent/PL2488512T3/pl unknown
- 2010-10-13 CA CA2968176A patent/CA2968176C/en active Active
- 2010-10-13 PT PT107683476T patent/PT2488512E/pt unknown
- 2010-10-13 PE PE2012000490A patent/PE20121137A1/es active IP Right Grant
- 2010-10-13 KR KR1020127012197A patent/KR101755742B1/ko active Active
- 2010-10-13 WO PCT/US2010/052433 patent/WO2011046997A1/en not_active Ceased
- 2010-10-13 HR HRP20140111AT patent/HRP20140111T1/hr unknown
- 2010-10-13 EA EA201270561A patent/EA020409B1/ru not_active IP Right Cessation
- 2010-10-13 SI SI201030486T patent/SI2488512T1/sl unknown
- 2010-10-13 KR KR1020187018446A patent/KR101990755B1/ko active Active
- 2010-10-13 JP JP2012534309A patent/JP5836279B2/ja active Active
- 2010-10-13 ES ES10768347.6T patent/ES2441192T3/es active Active
- 2010-10-13 RS RS20140035A patent/RS53149B/sr unknown
- 2010-10-13 CA CA2777518A patent/CA2777518C/en active Active
- 2010-10-14 AR ARP100103755A patent/AR078638A1/es not_active Application Discontinuation
- 2010-10-14 TW TW099135091A patent/TWI465448B/zh active
-
2012
- 2012-03-28 TN TNP2012000139A patent/TN2012000139A1/en unknown
- 2012-04-05 IL IL219120A patent/IL219120A/en active IP Right Grant
- 2012-04-12 CL CL2012000925A patent/CL2012000925A1/es unknown
- 2012-04-26 CO CO12068979A patent/CO6460732A2/es unknown
- 2012-05-11 ZA ZA2012/03452A patent/ZA201203452B/en unknown
- 2012-10-16 US US13/652,690 patent/US20130053570A1/en not_active Abandoned
-
2014
- 2014-02-17 SM SM201400019T patent/SMT201400019B/xx unknown
-
2015
- 2015-04-30 JP JP2015092727A patent/JP6109874B2/ja active Active
-
2017
- 2017-03-08 JP JP2017043761A patent/JP6258537B2/ja active Active
- 2017-11-13 AR ARP170103159A patent/AR110069A2/es not_active Application Discontinuation
-
2022
- 2022-07-12 CY CY2022023C patent/CY2022023I1/el unknown
- 2022-07-14 NL NL301187C patent/NL301187I2/nl unknown
- 2022-07-18 HU HUS2200033C patent/HUS2200033I1/hu unknown
- 2022-07-19 LU LU00272C patent/LUC00272I2/fr unknown
- 2022-07-22 NO NO2022033C patent/NO2022033I1/no unknown
- 2022-08-02 LT LTPA2022516C patent/LTC2488512I2/lt unknown
- 2022-08-11 FR FR22C1044C patent/FR22C1044I2/fr active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7418395B2 (ja) | Ｓｈｐ２ホスファターゼ阻害剤およびこれらの使用方法 | |
| AU2018255300B2 (en) | Bicyclic compounds and their use in the treatment of cancer | |
| ES2985528T3 (es) | Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de enfermedades | |
| TWI896747B (zh) | 快速加速纖維肉瘤蛋白質降解之化合物及包含其之組成物 | |
| KR101823488B1 (ko) | 선택적으로 치환된 퀴놀린 화합물 | |
| AU2015296322B2 (en) | 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as CDK inhibitors and uses thereof | |
| HRP20140111T1 (hr) | Antagonisti receptora za cgrp | |
| AU2022261029A1 (en) | Heterocyclic derivative inhibitor and preparation method therefor and application thereof | |
| US11590116B2 (en) | Substituted pyridines and methods of use | |
| JP6285918B2 (ja) | テトラヒドロピラゾロピリミジン化合物 | |
| JP6133291B2 (ja) | ピラゾロ［３，４−ｃ］ピリジン化合物と使用方法 | |
| ES2738823T3 (es) | Moduladores heterocíclicos de la síntesis de lípidos | |
| HUE028723T2 (en) | Piperidin-4-yl azetidine derivatives as JAK-1 inhibitors | |
| TW202015677A (zh) | 用於治療疾病之新穎化合物及其醫藥組合物 | |
| JP2015521645A (ja) | ５−アザインダゾール化合物及び使用方法 | |
| CA2845159A1 (en) | Compounds and compositions as c-kit kinase inhibitors | |
| CA2983342A1 (en) | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| JP2018530557A (ja) | 置換ピラゾロ［３，４−ｂ］ピリジン−６−カルボン酸およびこの使用 | |
| WO2021032323A1 (en) | Fused pyrimidine compounds and pharmaceutical compositions thereof for the treatment of fibrotic diseases | |
| CA3106131A1 (en) | P2x3 receptor antagonists | |
| CA3246898A1 (en) | HETEROCYCLIC NITROGEN-CONTAINING COMPOUND HAVING AN NRF2-ACTIVATING EFFECT | |
| AU2019363662B2 (en) | 5-azaindazole derivatives as adenosine receptor antagonists | |
| JP2009535429A5 (enExample) | ||
| EP4444421A2 (en) | Heterocyclic compounds as dyrk1a inhibitors | |
| JP6703989B2 (ja) | 呼吸器合胞体ウイルス（ｒｓｖ）の複製への阻害活性を有するピペリジン置換三環式ピラゾロ［１，５−ａ］ピリミジン誘導体 |